Ticker brief
AXSM AXSOME THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$244.31
1 day
+1.5%
14 days
-2.5%
mkt cap
$12.6B
signals 14d
7
authors 14d
7
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-06-26 · now +0.26 (−1 bearish … +1 bullish)
Who spoke7
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -0.75 | 1 | +0.55 |
| @fj_nextstage | C | +1.07 | 1 | -0.15 |
| @BioStocks | C | -0.39 | 1 | +0.20 |
| @CrweWorld | C | · | 1 | +0.30 |
| @OzmosiHealth | C | · | 1 | +0.20 |
| @cfromhertz | B | +0.07 | 1 | +0.45 |
| @BiopharmIQ | B | · | 1 | +0.15 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-26 | @BiopharmIQ | +0.15 | Biotech open news list with price moves and discrete catalysts, capped to six tickers. | +1.1% | tweet ↗ |
| 2026-06-26 | @cfromhertz | +0.45 | AXSM is bouncing from defined support at June value area. | +1.1% | tweet ↗ |
| 2026-06-26 | @OzmosiHealth | +0.20 | Axsome initiates FOCUS-3 Phase 3 trial of Solriamfetol in adolescents with ADHD. | +1.1% | tweet ↗ |
| 2026-06-26 | @CrweWorld | +0.30 | Axsome initiates Phase 3 trial of Solriamfetol in adolescent ADHD. | +1.1% | tweet ↗ |
| 2026-06-26 | @BioStocks | +0.20 | AXSM initiates Phase 3 trial with patient count, randomization and primary endpoint details. | +1.1% | tweet ↗ |
| 2026-06-25 | @fj_nextstage | -0.15 | IBD50 additions/removals with author skeptical of volatile additions. | +2.9% | tweet ↗ |
| 2026-06-24 | @semodough | +0.55 | Oppenheimer-hosted management comments cite Auvelity script momentum and peak sales guidance rising to about $8B. | +2.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.